Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
Shihab, H.M.; Lutwama, F.; Piloya, T.; Castelnuovo, B.; Kambugu, A.D.; Colebunders, R.
Journal of Infection in Developing Countries 3(5): 405-407
2009
ISSN/ISBN: 1972-2680 PMID: 19759513 Document Number: 208549
A large number of patients are switched to second-line antiretroviral therapy, especially in resource limited settings. Lopinavir/Ritonavir is the main drug used in second-line treatment regimens. We describe a patient attending an HIV treatment centre in Kampala, Uganda, who presented with bilateral non-tender pitting inflammatory edema two weeks after switching to a Lopinavir/Ritonavir-containing second-line treatment regimen. The lack of an alternate explanation led us to suspect that Lopinavir/Ritonavir was potentially responsible for the edema.
Document emailed within 1 workday
Related Documents
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113Chrysos, G.; Mikros, S.; Kokkoris, S.; Pastelli, A.; Kontochristopoulos, G. 2007: Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient Journal of Drugs in Dermatology: Jdd 6(7): 742-743
Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
Luque, A.E.; Cohn, S.E.; Park, J.-G.; Cramer, Y.; Weinberg, A.; Livingston, E.; Klingman, K.L.; Aweeka, F.; Watts, D.H. 2015: Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study Antimicrobial Agents and ChemoTherapy 59(4): 2094-2101
Sunpath, H.; Winternheimer, P.; Cohen, S.; Tennant, I.; Chelin, N.; Gandhi, R.T.; Murphy, R.A. 2014: Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 18(6): 689-693
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Kremp, A.; Poppe, H. 1980: Informative potential of computer-aided tomography (CAT), as compared to bilateral pedal lymphangiography, for the detection of gynaecological tumours, with particular reference to carcinoma of the cervix Zentralblatt für Gynakologie 102(21): 1213-1222
Murphy, R.A.; Marconi, V.C.; Gandhi, R.T.; Kuritzkes, D.R.; Sunpath, H. 2012: Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa Plos one 7(9): E44793
Estrela, R.C.E.; Santoro, A.B.; Barroso, P.F.; Tuyama, M.; Suarez-Kurtz, G. 2008: CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects Clinical Pharmacology and Therapeutics 84(2): 205-207
Musiime, V.; Fillekes, Q.; Kekitiinwa, A.; Kendall, L.; Keishanyu, R.; Namuddu, R.; Young, N.; Opilo, W.; Lallemant, M.; Walker, A.S.; Burger, D.; Gibb, D.M. 2014: The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children Journal of Acquired Immune Deficiency Syndromes 66(2): 148-154
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Bartelink, I.H.; Savic, R.M.; Mwesigwa, J.; Achan, J.; Clark, T.; Plenty, A.; Charlebois, E.; Kamya, M.; Young, S.L.; Gandhi, M.; Havlir, D.; Cohan, D.; Aweeka, F. 2014: Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda Journal of Clinical Pharmacology 54(2): 121-132
Colombo, S.; Buclin, T.; Franc, C.; Guignard, N.; Khonkarly, M.; Tarr, P.E.; Rochat, B.; Biollaz, J.ér.ôm.; Telenti, A.; Decosterd, L.A.; Cavassini, M. 2006: Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures Antiviral Therapy 11(1): 53-62
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Nagot, N.; Kankasa, C.; Meda, N.; Hofmeyr, J.; Nikodem, C.; Tumwine, J.K.; Karamagi, C.; Sommerfelt, H.; Neveu, D.; Tylleskär, T.; Van de Perre, P. 2012: Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174 Bmc Infectious Diseases 12: 246
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Kitaoka, T.; Nakayama, F.; Koshikawa, S. 1980: Science of symptoms. Edema: treatment of edema--classification of edema and key points in clinical management Nursing Technique 26(4): 504-511